Publications by authors named "Shivaani Kummar"

100Publications

Evaluation of Pharmacodynamic Responses to Cancer Therapeutic Agents Using DNA Damage Markers.

Clin Cancer Res 2019 05 21;25(10):3084-3095. Epub 2019 Feb 21.

Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-2523DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6522288PMC
May 2019

TRK Inhibition: A New Tumor-Agnostic Treatment Strategy.

Target Oncol 2018 10;13(5):545-556

Department of Oncology, Rigshospitalet, DK-2100, Copenhagen Ø, Denmark.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11523-018-0590-1DOI Listing
October 2018

A Phase I Study of Ganetespib and Ziv-Aflibercept in Patients with Advanced Carcinomas and Sarcomas.

Oncologist 2018 11 31;23(11):1269-e125. Epub 2018 May 31.

Early Clinical Trials Development Program, Developmental Therapeutics Clinic, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA

View Article

Download full-text PDF

Source
http://theoncologist.alphamedpress.org/lookup/doi/10.1634/th
Publisher Site
http://dx.doi.org/10.1634/theoncologist.2018-0203DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291327PMC
November 2018

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.

N Engl J Med 2018 02;378(8):731-739

From Memorial Sloan Kettering Cancer Center (A. Drilon, J.F.H., R.B., M.L., D.M.H.) and Weill Cornell Medical College (A. Drilon, D.M.H.), New York; University of Texas Southwestern Medical Center-Children's Health, Dallas (T.W.L.); Stanford Cancer Center, Stanford University, Palo Alto (S.K.), Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California (L.M.), and UCLA David Geffen School of Medicine (N.F.), Los Angeles, and Loxo Oncology, South San Francisco (B.B.T., K.E., S.C., N.C.K., M.C.C.) - all in California; Dana-Farber-Boston Children's Cancer and Blood Disorders Center (S.G.D.), Dana-Farber Cancer Institute (G.D.D., M.N.), Ludwig Center at Harvard (G.D.D.), and Massachusetts General Hospital (A.F.F.) - all in Boston; the Finsen Center, Rigshospitalet, Copenhagen (U.N.L.); University of Colorado, Aurora (R.C.D.); St. Jude Children's Research Hospital, Memphis (A.S.P.), and Vanderbilt University, Nashville (J.B.) - both in Tennessee; Cincinnati Children's Hospital Medical Center, Cincinnati (B.T.); University Hospitals of Cleveland Medical Center (A. Dowlati) and Taussig Cancer Institute, Cleveland Clinic (D.P.S.S.), Cleveland; University of Pennsylvania Perelman School of Medicine, Department of Otorhinolaryngology and Head and Neck Surgery, and the Abramson Cancer Center (M.S.B.), and Fox Chase Cancer Center (W.S.E.-D.), Philadelphia; University of Washington-Seattle Cancer Care Alliance (C.B.), Seattle Children's Hospital (E.R.R.), and Seattle Children's Hospital, University of Washington, Fred Hutchinson Cancer Research Center (D.S. Hawkins), Seattle; University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B., D.S. Hong); Inova Schar Cancer Institute, Falls Church, VA (J.D.); START Madrid, Centro Integral Oncológico Clara Campal, Madrid (V.B.); Nemours Children's Hospital, Orlando (R.N.), and Memorial Cancer Institute-Florida International University, Miami (L.E.R.) - both in Florida; Oregon Health and Science University, Portland (M.T.); and WVU Cancer Institute, West Virginia University, Morgantown (P.C.M.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1714448DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5857389PMC
February 2018

The evolving paradigm of cancer trials.

Authors:
Shivaani Kummar

Nat Rev Drug Discov 2018 04 22;17(4):225-226. Epub 2017 Dec 22.

Stanford University School of Medicine, 780 Welch Road, CJ250L, Palo Alto, California 94305, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrd.2017.210DOI Listing
April 2018

Molecular insights into desmoid tumors.

Oncotarget 2017 Oct 28;8(53):90608-90609. Epub 2017 Sep 28.

Shivaani Kummar: Division of Medical Oncology, Stanford Univeristy School of Medicine, Palo Alto, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.21293DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5710859PMC
October 2017

Evolution of early phase clinical trials in oncology.

J Mol Med (Berl) 2018 01 24;96(1):31-38. Epub 2017 Nov 24.

Division of Medical Oncology, Stanford University School of Medicine, 780 Welch Road, CJ250L, Palo Alto, CA, 94305, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00109-017-1612-7DOI Listing
January 2018

Dosimetry and first human experience with Zr-panitumumab.

Am J Nucl Med Mol Imaging 2017 1;7(4):195-203. Epub 2017 Sep 1.

Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of HealthBethesda, MD, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5596322PMC
September 2017

Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial.

Clin Cancer Res 2017 Aug 18;23(16):4550-4555. Epub 2017 Apr 18.

Cancer Center and Departments of Cell Biology and Biochemistry, Pediatrics, and Medicine, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-17-0234DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559312PMC
August 2017

Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis).

J Clin Oncol 2017 May 28;35(14):1561-1569. Epub 2017 Mar 28.

Shivaani Kummar, Geraldine O'Sullivan Coyne, Khanh T. Do, Baris Turkbey, Paul S. Meltzer, Eric Polley, Peter L. Choyke, Robert Meehan, Yvonne Horneffer, Ann Lih, Amul Choudhary, Sandra A. Mitchell, Lee J. Helman, James H. Doroshow, and Alice P. Chen, National Cancer Institute, National Institutes of Health, Bethesda; and Rasa Vilimas and Lamin Juwara, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.1994DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455706PMC
May 2017

Promise and limits of the CellSearch platform for evaluating pharmacodynamics in circulating tumor cells.

Semin Oncol 2016 08 15;43(4):464-75. Epub 2016 Jun 15.

Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc, Frederick National Laboratory for Cancer Research, Frederick, MD. Electronic address:

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074690PMC
http://dx.doi.org/10.1053/j.seminoncol.2016.06.004DOI Listing
August 2016

Establishing proof of mechanism: Assessing target modulation in early-phase clinical trials.

Semin Oncol 2016 08 14;43(4):446-52. Epub 2016 Jun 14.

National Cancer Institute, National Institutes of Health, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2016.06.002DOI Listing
August 2016

LC-MS/MS assay for the quantitation of FdCyd and its metabolites FdUrd and FU in human plasma.

J Pharm Biomed Anal 2016 Sep 18;129:359-366. Epub 2016 Jul 18.

Cancer Therapeutics Drug Discovery Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, United States; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, United States; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpba.2016.07.027DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5003709PMC
September 2016

Developing therapies for rare tumors: opportunities, challenges and progress.

Expert Opin Orphan Drugs 2016 9;4(1):93-103. Epub 2015 Dec 9.

Stanford University School of Medicine, Stanford, CA 94304, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/21678707.2016.1120663DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7405963PMC
December 2015

Gastric cancer: Geographic differences in multidisciplinary management.

Authors:
Shivaani Kummar

Curr Probl Cancer 2015 Nov-Dec;39(6):314. Epub 2015 Dec 2.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.currproblcancer.2015.11.001DOI Listing
August 2016

Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT Trial.

J Mol Diagn 2016 Jan 18;18(1):51-67. Epub 2015 Nov 18.

Molecular Characterization and Clinical Assay Development Laboratory, Leidos Biomedical Research Inc., and Frederick National Laboratory for Cancer Research, Frederick, Maryland; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jmoldx.2015.07.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5812775PMC
January 2016

Delivering on the promise: poly ADP ribose polymerase inhibition as targeted anticancer therapy.

Curr Opin Oncol 2015 Nov;27(6):475-81

aDivision of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland bDivision of Medical Oncology, Department of Medicine, Stanford University, Stanford, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000238DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4636335PMC
November 2015

Oral and intravenous pharmacokinetics of 5-fluoro-2'-deoxycytidine and THU in cynomolgus monkeys and humans.

Cancer Chemother Pharmacol 2015 Oct 1;76(4):803-11. Epub 2015 Sep 1.

Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA, 15213, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-015-2857-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4573928PMC
October 2015

Inhibitory Effect of the Noncamptothecin Topoisomerase I Inhibitor LMP-400 on Female Mice Models and Human Pheochromocytoma Cells.

Endocrinology 2015 Nov 12;156(11):4094-104. Epub 2015 Aug 12.

Program in Reproductive and Adult Endocrinology (J.S., P.B., Y.T., A.G., N.L., S.N., K.P.), Eunice Kennedy Shriver National Institute of Child Health and Human Development, Warren G. Magnuson Clinical Center (R.W.), and National Cancer Institute (Y.P., S.K.), National Institutes of Health, Bethesda, Maryland 20892-1109; Department of Internal Medicine III-Nephrology, Rheumatology, and Endocrinology (J.S., Z.F.), Faculty of Medicine and Dentistry, Palacky University, 771 47 Olomouc, Czech Republic; Department of Molecular Medicine (P.B., J.K.), Institute of Virology, Slovak Academy of Sciences, 845 05 Bratislava, Slovak Republic; and Department of Internal Medicine II (S.N.), Campus Grosshadern, University-Hospital of the Ludwig-Maximilians-University of Munich, 80539 Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/en.2015-1476DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4606751PMC
November 2015

Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors.

J Clin Oncol 2015 Oct 11;33(30):3409-15. Epub 2015 May 11.

Khanh Do, Jennifer Zlott, Jerry Collins, Alice P. Chen, James H. Doroshow, and Shivaani Kummar, National Cancer Institute, Bethesda, MD; Deborah Wilsker, Jiuping Ji, and Robert J. Kinders, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD; and Tomoko Freshwater, Merck Research Laboratories-Oncology, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.4009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4606059PMC
October 2015

Application of molecular profiling in clinical trials for advanced metastatic cancers.

J Natl Cancer Inst 2015 Apr 6;107(4). Epub 2015 Feb 6.

Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD (SK, ECP, APC, LVR, YZ, RMS, BAC, JHD); Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD (PMW, CJL).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djv003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334817PMC
April 2015

Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer.

Invest New Drugs 2015 Jun 1;33(3):720-8. Epub 2015 Feb 1.

Division of Cancer Treatment and Diagnosis, National Cancer Institute, 31 Center Drive, Bldg 31, Rm 3A44, Bethesda, MD, 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-015-0212-zDOI Listing
June 2015

New, tolerable γ-secretase inhibitor takes desmoid down a notch.

Clin Cancer Res 2015 Jan 21;21(1):7-9. Epub 2014 Oct 21.

Department of Pathology and Sarcoma Research Center, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-1660DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4306586PMC
January 2015

Translational research in oncology--10 years of progress and future prospects.

Nat Rev Clin Oncol 2014 Nov 7;11(11):649-62. Epub 2014 Oct 7.

Division of Cancer Treatment and Diagnosis, Room 3A-44, Building 31, 31 Center Drive, National Cancer Institute, NIH, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2014.158DOI Listing
November 2014

Paraneoplastic neurologic manifestations of malignancies. Foreword.

Authors:
Shivaani Kummar

Curr Probl Cancer 2014 Jul-Aug;38(4):114. Epub 2014 Aug 12.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.currproblcancer.2014.08.001DOI Listing
May 2015

Validation of a hypoxia-inducible factor-1 alpha specimen collection procedure and quantitative enzyme-linked immunosorbent assay in solid tumor tissues.

Anal Biochem 2014 Aug 4;459:1-11. Epub 2014 May 4.

Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA; Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00032697140017
Publisher Site
http://dx.doi.org/10.1016/j.ab.2014.04.025DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4810780PMC
August 2014

Cabozantinib-induced thyroid dysfunction: a review of two ongoing trials for metastatic bladder cancer and sarcoma.

Thyroid 2014 Aug 5;24(8):1223-31. Epub 2014 Jun 5.

1 National Institute of Diabetes and Digestive and Kidney Diseases, Diabetes, Endocrine, and Obesity Branch, National Institutes of Health , Bethesda, Maryland.

View Article

Download full-text PDF

Source
https://www.liebertpub.com/doi/10.1089/thy.2013.0621
Publisher Site
http://dx.doi.org/10.1089/thy.2013.0621DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4106376PMC
August 2014

Wee1 kinase as a target for cancer therapy.

Cell Cycle 2013 Oct 26;12(19):3159-64. Epub 2013 Aug 26.

Center for Cancer Research; National Cancer Institute; Bethesda, MD USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cc.26062DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3865011PMC
October 2013

LC-MS/MS assay for the quantitation of the HDAC inhibitor belinostat and five major metabolites in human plasma.

J Pharm Biomed Anal 2013 Jul-Aug;81-82:89-98. Epub 2013 Apr 9.

Molecular Therapeutics Drug Discovery Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213-1863, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpba.2013.03.025DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3663884PMC
December 2013

Molecular targets in cancer therapy.

Expert Rev Anticancer Ther 2013 Mar;13(3):267-9

Division of Cancer Treatment and Diagnosis and Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1586/era.12.170
Publisher Site
http://dx.doi.org/10.1586/era.12.170DOI Listing
March 2013

Safety and feasibility of targeted agent combinations in solid tumours.

Nat Rev Clin Oncol 2013 Mar 29;10(3):154-68. Epub 2013 Jan 29.

Division of Cancer Treatment and Diagnosis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 31, Room 3A44, 31 Center Drive, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2012.245DOI Listing
March 2013

Development and validation of an immunoassay for quantification of topoisomerase I in solid tumor tissues.

PLoS One 2012 28;7(12):e50494. Epub 2012 Dec 28.

Laboratory of Human Toxicology and Pharmacology, Applied/Developmental Research Support Directorate, SAIC-Frederick, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0050494PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3532478PMC
June 2013

Antiangiogenic approaches for the treatment of advanced synovial sarcomas.

Curr Opin Oncol 2012 Jul;24(4):425-30

Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0b013e328354c141DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7442297PMC
July 2012

Advances in using PARP inhibitors to treat cancer.

BMC Med 2012 Mar 9;10:25. Epub 2012 Mar 9.

Division of Cancer Treatment and Diagnosis, 31 Center Drive, National Cancer Institute, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1741-7015-10-25DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3312820PMC
March 2012

Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia.

Clin Cancer Res 2012 Apr 3;18(7):2099-107. Epub 2012 Feb 3.

Clinical Pharmacology Program, Pharmacology and Experimental Therapeutics Section, Molecular Pharmacology Section, Biostatistics and Data Management Branch, Medical Oncology Branch, and HIV/AIDS Malignancy Branch, National Cancer Institute, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-11-2484DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6432766PMC
April 2012

Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent.

Cell Cycle 2011 Dec 1;10(23):4074-82. Epub 2011 Dec 1.

Division of Cancer Treatment and Diagnosis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/abs/10.4161/cc.10.23.18170
Publisher Site
http://dx.doi.org/10.4161/cc.10.23.18170DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3272289PMC
December 2011

A phase I study of the chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer.

Clin Colorectal Cancer 2011 Jun 22;10(2):85-96. Epub 2011 Apr 22.

Department of Medicine and Pharmacology, Developmental Therapeutics Program, Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2011.03.003DOI Listing
June 2011

Phase I trial of fenretinide lym-x-sorb oral powder in adults with solid tumors and lymphomas.

Anticancer Res 2011 Mar;31(3):961-6

National Cancer Institute, Building 31, Room 3A44, 31 Center Drive, National Institutes of Health, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357208PMC
March 2011

Population pharmacokinetic analysis of sorafenib in patients with solid tumours.

Br J Clin Pharmacol 2011 Aug;72(2):294-305

Clinical Pharmacology Program Medical Oncology Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2125.2011.03963.xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162659PMC
August 2011

Phase 0 trials: expediting the development of chemoprevention agents.

Cancer Prev Res (Phila) 2011 Mar;4(3):288-92

Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1940-6207.CAPR-11-0013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3077921PMC
March 2011

Adenocarcinoma of the small bowel: changes in the landscape?

Curr Opin Oncol 2010 Jul;22(4):387-93

Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0b013e32833a86feDOI Listing
July 2010

The statistics of phase 0 trials.

Stat Med 2010 May;29(10):1072-6

Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902019PMC
http://dx.doi.org/10.1002/sim.3840DOI Listing
May 2010

Advances in the treatment of metastatic colorectal cancer.

Am J Ther 2009 Sep-Oct;16(5):412-20

Department of Hematology/Oncology, University of Oklahoma, Oklahoma City, OK, USA.

View Article

Download full-text PDF

Source
http://search.proquest.com/openview/d07f3055552aff19767273a1
Web Search
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/MJT.0b013e3181907ed9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2789349PMC
February 2010

Targeting mitogen-activated protein kinase kinase (MEK) in solid tumors.

Target Oncol 2009 Dec 10;4(4):267-73. Epub 2009 Nov 10.

Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, 9000 Rockville Pike, 10/13N240G, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11523-009-0125-xDOI Listing
December 2009

Role of Phase 0 trials in drug development.

Future Med Chem 2009 Nov;1(8):1375-80

Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://www.future-science.com/doi/10.4155/fmc.09.117
Publisher Site
http://dx.doi.org/10.4155/fmc.09.117DOI Listing
November 2009